HRP20040665B1 - Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment - Google Patents
Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatmentInfo
- Publication number
- HRP20040665B1 HRP20040665B1 HRP20040665A HRP20040665B1 HR P20040665 B1 HRP20040665 B1 HR P20040665B1 HR P20040665 A HRP20040665 A HR P20040665A HR P20040665 B1 HRP20040665 B1 HR P20040665B1
- Authority
- HR
- Croatia
- Prior art keywords
- compounds
- treatment
- methods
- compositions containing
- fluoro substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35138402P | 2002-01-24 | 2002-01-24 | |
| PCT/CA2003/000084 WO2003062200A2 (en) | 2002-01-24 | 2003-01-22 | Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20040665A2 HRP20040665A2 (en) | 2005-04-30 |
| HRP20040665B1 true HRP20040665B1 (en) | 2012-11-30 |
Family
ID=27613492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040665 HRP20040665B1 (en) | 2002-01-24 | 2004-07-19 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US20030158246A1 (sv) |
| EP (3) | EP2295409B1 (sv) |
| JP (2) | JP4008885B2 (sv) |
| KR (2) | KR20070056166A (sv) |
| CN (3) | CN101092388A (sv) |
| AR (1) | AR038136A1 (sv) |
| AT (1) | ATE414690T1 (sv) |
| AU (1) | AU2003202343B2 (sv) |
| BR (1) | BR0307050A (sv) |
| CA (1) | CA2471952C (sv) |
| CY (3) | CY1108841T1 (sv) |
| DE (2) | DE60324767D1 (sv) |
| DK (2) | DK1470107T3 (sv) |
| DO (1) | DOP2003000566A (sv) |
| EA (1) | EA006134B1 (sv) |
| EC (1) | ECSP045203A (sv) |
| EG (1) | EG24978A (sv) |
| ES (2) | ES2391747T3 (sv) |
| FR (1) | FR09C0010I2 (sv) |
| GE (1) | GEP20074078B (sv) |
| HR (1) | HRP20040665B1 (sv) |
| IL (3) | IL162825A0 (sv) |
| IS (2) | IS2633B (sv) |
| JO (1) | JO2481B1 (sv) |
| LU (1) | LU91534I2 (sv) |
| MX (1) | MXPA04007167A (sv) |
| MY (1) | MY137040A (sv) |
| NL (1) | NL300377I2 (sv) |
| NO (3) | NO327322B1 (sv) |
| NZ (1) | NZ533786A (sv) |
| PE (1) | PE20030982A1 (sv) |
| PL (1) | PL208527B1 (sv) |
| PT (2) | PT2045241E (sv) |
| RS (2) | RS51672B (sv) |
| SI (2) | SI2045241T1 (sv) |
| TW (1) | TWI259080B (sv) |
| UA (1) | UA75520C2 (sv) |
| WO (1) | WO2003062200A2 (sv) |
| ZA (1) | ZA200404999B (sv) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7273883B2 (en) * | 2000-09-14 | 2007-09-25 | Allergan, Inc. | Prostaglandin EP4 antagonist |
| US7217725B2 (en) * | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| WO2004104205A2 (en) * | 2003-05-16 | 2004-12-02 | Merck & Co., Inc. | Enzymatic preparation of chiral indole esters |
| WO2004103970A1 (en) * | 2003-05-20 | 2004-12-02 | Merck Frosst Canada Ltd. | Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| ATE464048T1 (de) * | 2003-08-07 | 2010-04-15 | Merck Sharp & Dohme | Behandlung von alzheimer-krankheit und verwandten zuständen |
| TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| CN1930162B (zh) | 2004-03-11 | 2010-06-16 | 埃科特莱茵药品有限公司 | 四氢吡啶并吲哚衍生物 |
| PT1737820E (pt) * | 2004-04-02 | 2008-03-17 | Merck & Co Inc | Processo de hidrogenação assimétrica útil para a preparação de derivados de cicloalcanoindole |
| GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| WO2006052798A2 (en) * | 2004-11-08 | 2006-05-18 | Merck & Co., Inc. | Method of treating pathological blushing |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| JPWO2006068162A1 (ja) * | 2004-12-24 | 2008-06-12 | 塩野義製薬株式会社 | 慢性閉塞性肺疾患の治療剤 |
| US8039474B2 (en) * | 2004-12-27 | 2011-10-18 | Actelion Pharmaceutical Ltd. | 2,3,4,9-tetrahydro-1H-carbazole derivatives as CRTH2 receptor antagonists |
| AU2006214018A1 (en) * | 2005-02-17 | 2006-08-24 | Merck Sharp & Dohme Corp. | Method of treating atherosclerosis, dyslipidemias and related conditions |
| EP1874301A4 (en) * | 2005-04-13 | 2009-05-06 | Merck & Co Inc | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SAME, AND METHODS OF TREATMENT |
| US7956082B2 (en) | 2005-07-22 | 2011-06-07 | Shionogi & Co., Ltd | Indole derivative having PGD2 receptor antagonist activity |
| JP5064219B2 (ja) | 2005-07-22 | 2012-10-31 | 塩野義製薬株式会社 | Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体 |
| WO2007029629A1 (ja) | 2005-09-06 | 2007-03-15 | Shionogi & Co., Ltd. | Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体 |
| HUE030850T2 (en) | 2006-06-16 | 2017-06-28 | Univ Pennsylvania | Prostaglandin D2 receptor antagonists for the treatment of hair loss |
| EP2051962B1 (en) | 2006-08-07 | 2011-10-26 | Actelion Pharmaceuticals Ltd. | (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives |
| US20100260841A1 (en) * | 2007-02-08 | 2010-10-14 | Paolini John F | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| US20090076117A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched laropiprant |
| EP2300425A4 (en) | 2008-06-24 | 2012-03-21 | Panmira Pharmaceuticals Llc | PROSTAGLANDIN D2 RECEPTOR CYCLOALCANEÝBINDLUCK ANTAGONISTS |
| WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
| US8685999B2 (en) | 2008-09-25 | 2014-04-01 | Merck Sharp & Dohme Corp. | Beta carboline sulphonylurea derivatives as EP4 receptor antagonists |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US9180114B2 (en) * | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
| US8882678B2 (en) * | 2009-03-13 | 2014-11-11 | Atrium Medical Corporation | Pleural drainage system and method of use |
| PL2558447T3 (pl) | 2010-03-22 | 2015-03-31 | Idorsia Pharmaceuticals Ltd | Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2 |
| EP2697223B1 (en) | 2011-04-14 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| JP5841361B2 (ja) * | 2011-06-29 | 2016-01-13 | 壽製薬株式会社 | 三環性化合物及びそれを含有する医薬組成物 |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102659664B (zh) * | 2012-03-28 | 2015-01-21 | 中国计量学院 | 合成分离拉洛皮兰及其类似物的方法 |
| FR3000395A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee |
| FR3000399B1 (fr) * | 2012-12-31 | 2015-03-27 | Galderma Res & Dev | Utilisation topique du laropiprant pour le traitement de la rosacee |
| UA117780C2 (uk) | 2014-03-17 | 2018-09-25 | Ідорсія Фармасьютікалз Лтд | Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2 |
| RU2016140708A (ru) | 2014-03-18 | 2018-04-18 | Идорсиа Фармасьютиклз Лтд | Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2 |
| US10351560B2 (en) | 2015-09-15 | 2019-07-16 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
| KR102465211B1 (ko) | 2018-03-19 | 2022-11-10 | 미쯔이가가꾸가부시끼가이샤 | 표시 소자용 밀봉재 및 그의 경화물, 유기 el 소자용 프레임 밀봉재, 그리고 유기 el 소자용 면 밀봉재 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3535326A (en) * | 1967-03-06 | 1970-10-20 | Sumitomo Chemical Co | Certain tetrahydro carboline derivatives |
| BE787444A (fr) * | 1971-08-13 | 1973-02-12 | Hoffmann La Roche | Composes polycycliques |
| US4009181A (en) * | 1973-01-22 | 1977-02-22 | Hoffmann-La Roche Inc. | Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof |
| US4057559A (en) * | 1973-10-01 | 1977-11-08 | American Home Products Corporation | Carbazole acetic acid derivatives |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4808608A (en) | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| IL81325A (en) | 1986-01-23 | 1990-11-29 | Merck Frosst Canada Inc | Tetrahydrocarbazole 1-alkanoic acids and pharmaceutical compositions containing them |
| US5021447A (en) * | 1986-01-23 | 1991-06-04 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions |
| US4940719A (en) * | 1986-03-27 | 1990-07-10 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole esters, pharmaceutical compositions and use |
| US4775680A (en) * | 1987-07-21 | 1988-10-04 | Merck & Co., Inc. | Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use |
| US5221678A (en) | 1990-07-26 | 1993-06-22 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| GB9101375D0 (en) | 1991-01-22 | 1991-03-06 | Erba Carlo Spa | N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole |
| AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| US5510332A (en) | 1994-07-07 | 1996-04-23 | Texas Biotechnology Corporation | Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor |
| AU2964295A (en) | 1994-07-11 | 1996-02-09 | Athena Neurosciences, Inc. | Inhibitors of leukocyte adhesion |
| US5811391A (en) | 1994-08-25 | 1998-09-22 | Cytel Corporation | Cyclic CS-1 peptidomimetics, compositions and methods of using same |
| GB9524630D0 (en) | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| AU5259296A (en) | 1995-04-07 | 1996-10-23 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of athero sclerosis |
| WO1996040781A1 (en) | 1995-06-07 | 1996-12-19 | Tanabe Seiyaku Co., Ltd. | CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION |
| JP3195361B2 (ja) | 1995-06-21 | 2001-08-06 | 塩野義製薬株式会社 | ビシクロ環系アミノ誘導体およびそれを含有するｐｇｄ２拮抗剤 |
| JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| PL191760B1 (pl) | 1996-12-13 | 2006-06-30 | Shionogi & Co | Związki, pochodne benzotiofenokarboksyamidu, związki pośrednie, kompozycja farmaceutyczna zawierająca te pochodne oraz lek do leczenia blokady nosa |
| ATE295183T1 (de) | 1998-06-03 | 2005-05-15 | Shionogi & Co | Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| US7019022B2 (en) * | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
-
2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/en not_active Expired - Lifetime
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 EP EP03700740A patent/EP1470107B1/en not_active Expired - Lifetime
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 EP EP08105552A patent/EP2045241B1/en not_active Expired - Lifetime
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 RS YU62404A patent/RS51672B/en unknown
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/en unknown
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Application Discontinuation
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en active Application Filing
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active IP Right Cessation
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
-
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-19 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
-
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
-
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
-
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
-
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
-
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
-
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040665B1 (en) | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | |
| HK1083835A1 (en) | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | |
| HK1081957A1 (en) | Benzopyranone compounds, compositions thereof, and methods of treatment therewith | |
| GB2393202B (en) | Methods of well treatment | |
| EP1680111A4 (en) | METHOD OF USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR TREATMENT, MODIFICATION AND CHECKING OF PAIN | |
| EP1560817A4 (en) | METHOD AND COMPOSITIONS OF NEW TRIAZINE COMPOUNDS | |
| HK1086485A1 (en) | Novel compounds, pharmaceutical compositions containing same, and methods of use for same | |
| PL373658A1 (en) | Treatment of gastroparesis | |
| EP1569915A4 (en) | SPIROCYCLIC UREAS, COMPOSITIONS CONTAINING SAME, AND METHODS OF USE | |
| EP1651231A4 (en) | CYCLOALKANES DIPHENYL-SUBSTITUTES, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND METHODS OF USE | |
| EP1667999A4 (en) | BENZOPYRANONE COMPOUNDS, COMPOSITIONS THEREOF, AND TREATMENT METHOD USING THE SAME | |
| IL175369A0 (en) | Novel compound, corresponding compositions, preparation and/or treatment methods | |
| EP1551388A4 (en) | COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME | |
| ZA200503240B (en) | Methods of using and compositions comprising immunodulatory compounds for treatment, modification and management of pain | |
| EP1575497A4 (en) | NEW COMPOSITION AND METHOD FOR TREATING PSORIASIS | |
| GB0324523D0 (en) | Compositions and methods of treatment | |
| GB0306309D0 (en) | Method of treatment | |
| GB0302572D0 (en) | Method of treatment | |
| PL352750A1 (en) | Novel isoindoloindolone compounds, method of obtaining them and pharamcological composition containing such compounds | |
| ZA200502376B (en) | Methods and compositions of novel triazine compounds | |
| AU2003225563A8 (en) | Compositions and methods for treatment of osteoarthritis | |
| GB0217493D0 (en) | Novel methods of treatment | |
| GB0208897D0 (en) | New method of treatment | |
| AU2003240174A8 (en) | Compositions for the treatment of edematous-firbrosclerotic panniculopathy | |
| GB0221712D0 (en) | Methods of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20140121 Year of fee payment: 12 |
|
| PBON | Lapse due to non-payment of renewal fee |
Effective date: 20150122 |